The study and its comparison
Sixty people reporting knee discomfort were randomized to calcium fructoborate or placebo. Researchers measured WOMAC and McGill pain scores after seven and fourteen days. [1]
Both measures favored the preparation at fourteen days. At seven days, the McGill comparison was significant, but the reported WOMAC comparison had a P value of 0.06. The numerical results therefore require more qualification than a blanket claim of benefit at both visits. [1]
What the finding establishes
Self-reported discomfort, a small sample and two weeks of observation limit conclusions about diagnosed arthritis and sustained function. Authors had affiliations with FutureCeuticals and NutraClinical; complete funding and conflict declarations were not established from the abstract. The amount of the entire fructoborate compound is not its elemental boron content. [1]
A hypothetical distinction
Imagine a label lists 110 milligrams of a boron-containing compound. That does not mean it supplies 110 milligrams of boron.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.